A low-code framework for automated test models generation

© 2024, [Elsevier]. This is an author produced version of a paper published in SoftwareX uploaded in accordance with the publisher’s self- archiving policy. The final published version (version of record) is available online at the link. Some minor differences between this version and the final published version may remain. We suggest you refer to the final published version should you wish to cite from it. The methodology under the term model-based software engineering (MBSE)gained importance already around 20 years ago, after the publication of theMDA initiative by the OMG. This development methodology continues toevolve, giving rise to recent proposals such as low-code or no-code. Somethingthat has not changed, as recent surveys point out, is the need for powerfultesting approaches and tools for these new methodologies. In MBSE, testinputs are models, so it is key to have frameworks for model generation.However, the main shortcomings of existing model-generation frameworksare their performance limitations and the need for domain-specific knowledge,which seriously hampers their industrial adoption. In this paper, we presentthe Yekta low-code framework that allows to generate models in a simpleway through the application of metaheuristic algorithms

A Graphene Based–biomimetic Molecularly Imprinted Polyaniline Sensor for Ultrasensitive Detection of Human Cardiac Troponin T(cTnT)

In the present work, a biomimetic nano-molecularly imprinted polymer (N-MIP) electrode based on a graphene screen-printed electrode was developed for the ultrasensitive detection of cardiac troponin T (cTnT). The biomimetic cavities for targeted sensing for analyte were fabricated by the electropolymerization of conductive co-polymer matrix of aniline and carboxylated aniline on the graphene oxide (GO) electrode, in the presence template protein (cTnT for cardiac troponin T probe) by cyclic voltammetry. The surface characterization of the sensor was performed using cyclic voltammetry (CV) and differential pulse voltammetry (DPV), and scanning electron microscopy (SEM). The best biomimetic surface nanotexture was obtained at aniline/carboxylatedaniline ratio of 1:4. The linear range of cTnT probe was in the range of 0.02 to 0.09 ng/mL, with the detection limit of 0.008 ng/mL. The reliability of the N-MIP cTnT sensor was examined by comparing the results with those obtained from HPLC method, and it was observed that the results from N-MIP sensors and HPLC have a great correlation

Intermittent Earth Fault Detection In Distribution Network Based On The Voting Classification Technique

Intermittent earth faults in non-effectively distribution networks, especially with underground cabling, can compromise the quality of the electricity supply. This type of earth fault may be followed by permanent faults, which in turn puts the networks on the line. This phenomenon monitoring can help distribution system operators (DSOs) to plan maintenance to reduce system interruption and improve MV electricity delivery. Thus, this research will examine AI-driven approaches, which are suitable for complicated issues, to improve distribution power grid monitoring and maintenance. The research focuses on medium and low-voltage grids and applies the voting classification technique (VC) to monitor and predict earth faults. Moreover, IEC 61850 Sampled Value communication protocol will be utilized at a practical level to establish a hierarchical infrastructure of data processing nodes. VC will process this raw data to determine the distribution network condition. In this endeavor, a new efficient way to monitor and maintain power networks will be examined. The suggested method will predict the existing and future status of the system, including upcoming breakdowns. At the top of the structure, aggregated information will be displayed to human grid operators to help them schedule maintenance or plan emergency actions. Real grid pilots and laboratory experiments in Finland will provide the required data to develop and train the suggested approach to predict intermittent earth faults.©2023 IET. This paper is a postprint of a paper submitted to and accepted for publication in 27th International Conference on Electricity Distribution (CIRED 2023) and is subject to Institution of Engineering and Technology Copyright. The copy of record is available at the IET Digital Library.fi=vertaisarvioitu|en=peerReviewed

Positronium imaging with the novel multiphoton PET scanner

In vivo assessment of cancer and precise location of altered tissues at initial stages of molecular disorders are important diagnostic challenges. Positronium is copiously formed in the free molecular spaces in the patient's body during positron emission tomography (PET). The positronium properties vary according to the size of inter- and intramolecular voids and the concentration of molecules in them such as, e.g., molecular oxygen, O2; therefore, positronium imaging may provide information about disease progression during the initial stages of molecular alterations. Current PET systems do not allow acquisition of positronium images. This study presents a new method that enables positronium imaging by simultaneous registration of annihilation photons and deexcitation photons from pharmaceuticals labeled with radionuclides. The first positronium imaging of a phantom built from cardiac myxoma and adipose tissue is demonstrated. It is anticipated that positronium imaging will substantially enhance the specificity of PET diagnostics.Comment: 10 pages, 5 figure

From tests of discrete symmetries to medical imaging with J-PET detector

We present results on CPT symmetry tests in decays of positronium performed with the precision at the level of 10$^{-4}$, and positronium images determined with the prototype of the J-PET tomograph. The first full-scale prototype apparatus consists of 192 plastic scintillator strips readout from both ends with vacuum tube photomultipliers. Signals produced by photomultipliers are probed in the amplitude domain and are digitized by FPGA-based readout boards in triggerless mode. In this contribution we report on the first two- and three-photon positronium images and tests of CPT symmetry in positronium decays

Testing CPT symmetry in ortho-positronium decays with positronium annihilation tomography

Charged lepton system symmetry under combined charge, parity, and time-reversal transformation (CPT) remains scarcely tested. Despite stringent quantum-electrodynamic limits, discrepancies in predictions for the electron–positron bound state (positronium atom) motivate further investigation, including fundamental symmetry tests. While CPT noninvariance effects could be manifested in non-vanishing angular correlations between final-state photons and spin of annihilating positronium, measurements were previously limited by knowledge of the latter. Here, we demonstrate tomographic reconstruction techniques applied to three-photon annihilations of ortho-positronium atoms to estimate their spin polarisation without magnetic field or polarised positronium source. We use a plastic-scintillator-based positron-emission-tomography scanner to record ortho-positronium (o-Ps) annihilations with single-event estimation of o-Ps spin and determine the complete spectrum of an angular correlation operator sensitive to CPT-violating effects. We find no violation at the precision level of 10−4, with an over threefold improvement on the previous measurement

Global, regional, and national burden of neurological disorders, 1990–2016 : a systematic analysis for the Global Burden of Disease Study 2016

Background: Neurological disorders are increasingly recognised as major causes of death and disability worldwide. The aim of this analysis from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 is to provide the most comprehensive and up-to-date estimates of the global, regional, and national burden from neurological disorders. Methods: We estimated prevalence, incidence, deaths, and disability-adjusted life-years (DALYs; the sum of years of life lost [YLLs] and years lived with disability [YLDs]) by age and sex for 15 neurological disorder categories (tetanus, meningitis, encephalitis, stroke, brain and other CNS cancers, traumatic brain injury, spinal cord injury, Alzheimer's disease and other dementias, Parkinson's disease, multiple sclerosis, motor neuron diseases, idiopathic epilepsy, migraine, tension-type headache, and a residual category for other less common neurological disorders) in 195 countries from 1990 to 2016. DisMod-MR 2.1, a Bayesian meta-regression tool, was the main method of estimation of prevalence and incidence, and the Cause of Death Ensemble model (CODEm) was used for mortality estimation. We quantified the contribution of 84 risks and combinations of risk to the disease estimates for the 15 neurological disorder categories using the GBD comparative risk assessment approach. Findings: Globally, in 2016, neurological disorders were the leading cause of DALYs (276 million [95% UI 247–308]) and second leading cause of deaths (9·0 million [8·8–9·4]). The absolute number of deaths and DALYs from all neurological disorders combined increased (deaths by 39% [34–44] and DALYs by 15% [9–21]) whereas their age-standardised rates decreased (deaths by 28% [26–30] and DALYs by 27% [24–31]) between 1990 and 2016. The only neurological disorders that had a decrease in rates and absolute numbers of deaths and DALYs were tetanus, meningitis, and encephalitis. The four largest contributors of neurological DALYs were stroke (42·2% [38·6–46·1]), migraine (16·3% [11·7–20·8]), Alzheimer's and other dementias (10·4% [9·0–12·1]), and meningitis (7·9% [6·6–10·4]). For the combined neurological disorders, age-standardised DALY rates were significantly higher in males than in females (male-to-female ratio 1·12 [1·05–1·20]), but migraine, multiple sclerosis, and tension-type headache were more common and caused more burden in females, with male-to-female ratios of less than 0·7. The 84 risks quantified in GBD explain less than 10% of neurological disorder DALY burdens, except stroke, for which 88·8% (86·5–90·9) of DALYs are attributable to risk factors, and to a lesser extent Alzheimer's disease and other dementias (22·3% [11·8–35·1] of DALYs are risk attributable) and idiopathic epilepsy (14·1% [10·8–17·5] of DALYs are risk attributable). Interpretation: Globally, the burden of neurological disorders, as measured by the absolute number of DALYs, continues to increase. As populations are growing and ageing, and the prevalence of major disabling neurological disorders steeply increases with age, governments will face increasing demand for treatment, rehabilitation, and support services for neurological disorders. The scarcity of established modifiable risks for most of the neurological burden demonstrates that new knowledge is required to develop effective prevention and treatment strategies. Funding: Bill & Melinda Gates Foundation

Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 29 cancer groups, 1990 to 2017 : A systematic analysis for the global burden of disease study

Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-Adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572000 deaths and 15.2 million DALYs), and stomach cancer (542000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601000 deaths and 17.4 million DALYs), TBL cancer (596000 deaths and 12.6 million DALYs), and colorectal cancer (414000 deaths and 8.3 million DALYs). Conclusions and Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care. © 2019 American Medical Association. All rights reserved.Peer reviewe